Why the success of your HTA will rely on real world evidence
The first in a trilogy of webinars focussed on the topic; Unlocking the value; the economic equation and part of the IMS Health Practical Insights series.
While it remains the gold standard, the feasibility of large scale randomised clinical trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology. Within the changing landscape of drug development, payers need robust evidence in order to accurately assess the value and efficacy of innovative treatments for both smaller patient populations and increasingly expensive medicines. Answering this paradigm is where real world evidence can step in.
Topics covered include:
•The HTA landscape – the challenges of assessing rare disease and cancer medicines
•How regulators consider RWE in HTAs
•Learnings from best practice in global markets
•Recent case studies – successes and failures
•The role of the regulator in the Cancer Drugs Fund
•How RWE can assist market access
RecordedFeb 11 201669 mins
Your place is confirmed, we'll send you email reminders
Paul Tunnah (Moderator) with Oksana Matviienko (Viseven), Bogdan Rakytskyi (Teva) and Chris Wade (Veeva Systems)
Pharmaceutical marketers are increasingly native multichannel practitioners, but building an effective and efficient campaign is challenging.
This is also because the digital landscape, and the number of options available is still rapidly evolving.
What are the best ways to choose the right channels and the right content? And how can you plan to optimize operations further by cutting down on costs and approval times?
This webinar brings together experts in digital marketing with case studies from a leading pharmaceutical company to keep you up to date with the latest technology and trends and provide practical advice on how to maximize your impact.
Within one hour, you’ll discover how to optimize and streamline all content-related processes within a single platform: starting with concept development and ending with the final launch. What is more, you will find out how to reuse and repurpose your ready-made content cost-effectively, as well as save time while adapting and updating content through its whole lifecycle.
•How to develop best practice and a winning multichannel strategy
•Making sure your content supports face-to-face interactions
•Transforming the commercial teams to deliver successful digital and multichannel projects
•How to innovate in multichannel, and the potential of future integration solutions
Andrew McConaghie (moderator), John Munson, Nemanja Jankovic and Nina Felton
Across Europe, a shift towards greater prevention, earlier diagnosis and treatment is needed in order to contain the growing cost of healthcare.
But how can healthcare systems make this transition – and how do pharmaceutical companies play a role in this, while also growing their market?
A forthcoming webinar hosted by pharmaphorum with sponsor PHOENIX group looks at how harnessing the data and expertise of pharmacies, and via greater engagement with patients, consumers and shoppers can meet this emerging need.
•Industry: how can pharma switch from treating a disease to earlier health management?
The role of preventative medicine, vaccines and early diagnosis explored
•The role of community pharmacies in prevention and health – increasing screening and diagnosis rates and facilitating appropriate medication
•How point of sale information in pharmacies can help generate a picture of patient groups and individuals. How loyalty card schemes support OTC and consumer spending patterns, which illuminate health needs, prescription patterns and purchasing behaviour
With a wealth of market and regulatory changes impacting the medtech sector, it’s time for digital technology to steer the direction of your future business. This expert webinar will evaluate how to strategically embed digital within your own organisation and explore the challenges and the opportunities for transforming customer relationships, driving commercial outcomes.
– Respond to the changing regulatory environment: how technology empowers your business
– Build a business case for digital transformation and gain organisational support
– Strengthen your customer relationships and improve engagement in a diverse payer landscape
– Learn from pharma (and other industries) to find opportunities and avoid pitfalls
– Measure impact and return on investment from digital engagement
Paul Tunnah (moderator), Angela McFarlane, Sarah Rickwood, Margaret Dolan and Timothy C. de Gavre
A digital debate analysing the future for biologics in the UK and the factor affecting market access in this territory. Our expert panel will cover a number of key topics including:
•Are the savings offered by biosimilars being used to innovate and take advantage of the exciting new biologic technologies or just filling in the NHS potholes?
•Will the industry continue to invest in cutting-edge research if the UK is not prepared to fund access to it
•In a post-Brexit world how can the UK continue to be a global leader at the cutting edge of biologics research?
Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans. Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales. Just as an engine needs a steady supply of fuel to run efficiently, prescriber-facing teams – the commercial engine of life sciences companies – need market access data and insights to accelerate brand success. Today, the challenge is optimizing this fuel supply, as market access and commercial teams often operate in a siloed way with regards to data, market changes and insights.
Join a vibrant conversation with industry leaders to discuss how the industry is changing and adapting to operationalize market access pull-through for improved commercial success.
Jameisha Brown, Eric Delente, Paulo Moreira, Christine Phillips, Andrew McConaghie
Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.
With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.
To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.
Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.
Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.
From this webinar you will:
– Learn the current state of commercial content and digital asset management in life sciences promotions
– Garner an understanding of how your organization compares to the industry
– Understand how to accelerate your content across the digital supply chain
Alastair Kent OBE, Malcolm Qualie, Sheela Upadhyaya, Sarah Rickwood, Moderated by Paul Tunnah
Over the past few years there has been a shift in the European pharmaceutical market landscape, with a rise in specialty medicines for diseases with narrow patient populations. Indeed, QuintilesIMS forecasts that, between 2013 and 2018, 94% of list price value growth will be in specialty medicines – with orphan drugs at the forefront of this trend.
On 10 April 2017, QuintilesIMS, in partnership with pharmaphorum presents a unique digital debate, bringing together a panel of senior industry experts, including participants from NICE, NHS England and Genetic Alliance UK to explore the pillars of commercial success for orphan drugs in Europe in the context of changes in reimbursement processes and broader future challenges, like Brexit.
Pierre-Yves Boisvert, Paulien Schul, Nina Felton and Andrew McConaghie
Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers. This puts them in a unique position in terms of being able to maximise the benefits that patients get from their medicines – however, healthcare systems and pharmaceutical companies frequently overlook this potential.
Pharmacists are especially well placed to help patients with multiple long-term conditions manage their health and medications, and pharmacist-led interventions have been shown to have a very significant impact on compliance and disease management in the community.
We present a webinar debate in which our expert panel will discuss how pharmaceutical companies can work in collaboration with pharmacists in Europe to help patients make the most of their medicines, help generate data to prove the value of these interventions, and above all get the right medicine to the right patients and consumers.
Join us and the PHOENIX group as we look at the practical steps needed to make this a reality. Key topics to be discussed include:
•The challenges of identifying the right patient population across European markets
•Understanding how pharmacists can play a greater role in patient care, e.g. improved adherence and outcomes
•How optimum use of pharmacy level information can contribute to providing ‘real world’ evidence of treatments
Professor Luca Pani, University of Miami, Angelika Joos,MSD (Europe) Inc. Ana Palma, Sobi, Belgium
2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.
With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?
pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.
Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
Topics up for discussion include:
•Integrating HTA and regulatory strategy – the best way forward
•Regional variation and implication – how to efficiently and effectively navigate EU market access
•Proving value – how to leverage real world evidence to meet increasing demands for observational data
•Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
Roberto Slepetys, Martin Pöhlchen, Gayatri Gopal, Andrew McConaghie
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
– The user perspective: perception, adoption and expectations today and tomorrow
– The technology perspective: biggest successes and most room for improvements
– The societal and regulatory perspective: cost and risks versus benefits and opportunities
Nina Felton, Nick Cooper Larry R Smith II and Andrew McConaghie (moderator)
Join us and PHOENIX group as we delve into the concept of current launch excellence and the role of patient insights in overcoming the multiple challenges the industry currently faces.
Key topics to be discussed include:
– The challenges of launching a product in Europe
– How pharma can improve its understanding of the process through the use of business intelligence
– How insights from new data can be applied to the process of launch excellence
– The role of real-world data in launch strategy
– The downstream effect of applying real-world data to product launch on patient outcomes.
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
Key topics to be discussed include:
– The burden of HCV
– The current market landscape
– The current patient access model and its impact on budget
– Cost efficiencies shown by modelling
– Cure versus lifetime treatment costs
Over the past 20 years, behavioural economics has identified factors that influence and determine how people behave, including alternative decision-making pathways and many cognitive biases and heuristics. Taking account of these helps to build a clear view of how healthcare customers think and behave in relation to your product in the real world.
This short masterclass explores ‘quantitative demand assessment research’ – what it is and how insights from behavioural economics can improve the application of this important tool in pharmaceutical market research.
The masterclass will:
•Introduce demand assessment research and why it is important to healthcare market research
•Discuss how insights from behavioural economics can improve quantitative demand assessment market research
•Highlight a range of techniques using behavioural economics that help you build a more accurate picture of your customers and market.
Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
– How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
– How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
– How real world video content can engage your key stakeholders and ensure customer insights drive action
John Grumitt, IDF/Diabetes UK, Prof Michael Trenell, Newcastle University, Dr Phil McEwan
Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.
This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
Malcolm Qualie, NHS England, Nina Pinwill, NICE, Katie Pascoe, ABPI, Angela McFarlane, IMS Health Toby Gosden, IMS Health
Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.
To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.
How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
John Smith, PAGB, Rob Darracott, Pharmacy Voice, Sandra Gidley, English Pharmacy Board
New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.
UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?
Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
Stephen Dorrell, Chair NHS Confederation, Leslie Galloway, EMIG, Prof. Mike Bewick, prev NHS England, Dr Rick Greville, ABPI
The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.
Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?
In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:
The impact of Brexit on UK Healthcare
The ramification of Brexit for pharma in the UK
What does the Brexit scenario mean for global pharma?
Thought leadership webinars within the pharmaceutical industry
pharmaphorum provides a digital podium for communicating thought leadership and innovation within pharma. Our webinars bring together different stakeholders from across the healthcare spectrum to drive fresh thinking and novel solutions that deliver better outcomes for patients.